Google Übersetzer
Transcode Therapeutics, Inc.
About
6.11USD-0.06 -0.99%
Closed • Updated at 19:33 GMT+00:00Market Cap$5.81M
Volume10.2K
Beta-0.14
RSI22.59
Transcode Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 27 2026
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
Apr 7 2026
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
Mar 3 2026
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
Mar 3 2026
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Canc...
Feb 23 2026
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Recent Videos
TransCode's Breakthrough in Cancer Immunotherapy! #CancerImmunotherapy #RNAtechnology
Apr 01, 2026
Comprar acciones de TransCode Therapeutics Inc: guía rápida (RNAZ)
Mar 02, 2026
$RNAZ Stock TransCode Therapeutics | WHY DID RNAZ SQUEEZE TODAY??? Short Squeeze Review
Feb 05, 2026
Innovative Biotech Developments and Healthcare Advancements
Feb 04, 2026